Iranitidine Tablets (Ranitidine Hydrochloride)
Ranitidine Hydrochloride 168mg
Tablet · Prescription medication
Iworld Pharmaceutical Co., Ltd.
MFDS item code 201309682 · Approved 2013.10.11
This product's status changed to Expired on 2023.10.11. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of acid-related diseases (such as ulcers); improvement of gastric mucosal lesions; prevention of Mendelson syndrome
This medication is effective for various gastrointestinal disorders such as gastric and duodenal ulcers, Zollinger-Ellison syndrome, and gastroesophageal reflux disease. It is administered to prevent Mendelson's syndrome before surgery and helps in the treatment of ulcers after surgery. Additionally, it is used for gastric and duodenal ulcers caused by non-steroidal anti-inflammatory drugs (NSAIDs). It is also effective in improving gastric mucosal lesions associated with acute and chronic gastritis, acute exacerbation of gastric disorders, and upper gastrointestinal bleeding. In summary, this medication is used to improve various gastric-related diseases and symptoms.
(Tablets) 150, 300 mg (Oral solution) 75 mg/sachet Adults Administer 150 mg of ranitidine orally twice daily, in the morning and at bedtime. Gastric and duodenal ulcers Administer 150 mg orally twice daily or 300 mg once daily at bedtime. A higher cure rate may be achieved, particularly in patients with duodenal ulcers, by administering 300 mg twice daily, in the morning and at bedtime. The dosage and administration are the same for combination therapy to treat ulcers caused by nonsteroidal anti-inflammatory drugs or to prevent gastric and duodenal ulcers during long-term use of nonsteroidal anti-inflammatory drugs. These conditions usually heal within 4 weeks, and those caused by nonsteroidal anti-inflammatory drugs usually heal within 8 weeks, although healing may occasionally take longer in some patients. For patients with recurrent ulcers who responded well to short-term treatment with this medicine, administer 150 mg once daily at bedtime as maintenance therapy. Reflux esophagitis Administer 150 mg twice daily for 8 weeks or 300 mg once daily before bedtime. The dose may be increased to 150 mg 4 times daily in patients with severe reflux esophagitis. Zollinger-Ellison syndrome Initiate treatment with 150 mg 3 times daily; the dose may be increased as needed. In severe cases, up to 6 g daily may be administered as directed by a physician. For upper gastrointestinal bleeding caused by peptic ulcers, acute stress ulcers, or acute gastric mucosal lesions, treatment is usually initiated with an injection. Once oral administration is possible, switch to oral treatment and administer 150 mg twice daily. Preanesthetic medication (prevention of Mendelson's syndrome) Administer 150 mg 2 hours before induction of anesthesia. In this case, it is preferable to also administer 150 mg on the night before surgery. Improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) in the following conditions: acute gastritis and acute exacerbation of chronic gastritis Administer 150 mg once daily at bedtime. Patients with renal impairment For patients with severe renal impairment and creatinine clearance of 50 mL/min or less, administer 150 mg once daily at bedtime. Depending on the patient's condition, the dosing interval may be extended to 12 hours or longer. Hemodialysis reduces the blood concentration of the medicine, so readjust the dosing schedule immediately after hemodialysis. Adjust the dose as appropriate according to age and symptoms.
Aged 8 〜 18 years: 150 mg (2 mg per kg of body weight) may be administered per dose, up to twice daily. Patients aged 12 years and older: Administer 75 mg orally twice daily (oral solution only).
This medication should not be used in patients who have had allergic reactions to this medication or its ingredients. It should not be administered to patients with a history of acute porphyria due to the risk of provoking seizures. Furthermore, patients who are genetically unable to break down lactose should not use this medication as it contains lactose. In patients with impaired kidney function, dosage should be reduced or the dosing interval should be increased as this medication may remain in the body for an extended period. Caution is also advised in patients with liver dysfunction. Patients with a history of drug allergies or elderly patients should be administered this medication carefully. Patients taking non-steroidal anti-inflammatory drugs may have an increased risk of gastrointestinal bleeding and should be monitored regularly. Gastric ulcer patients or those with new dyspeptic symptoms in middle age or older should verify malignancy status before use, as this medication may mask gastric cancer symptoms. Patients with Helicobacter pylori-associated gastric or duodenal ulcers should undergo eradication treatment simultaneously. This medication can rarely cause serious allergic reactions, blood abnormalities, liver dysfunction, cardiac rhythm issues, gastrointestinal symptoms, neurological disorders, and skin rashes. If any unusual symptoms occur, take the medication off immediately and consult a doctor. It is important to have regular blood, liver, and kidney function tests during treatment. Elderly patients or those with chronic diseases may be at increased risk of pneumococcal infections and should be cautious. Avoid driving or operating dangerous machinery if dizziness or drowsiness occurs after taking this medication. Be sure to inform your doctor or pharmacist of any other medications being taken due to potential drug interactions, especially with drugs that affect blood coagulation. This medication should be administered cautiously in pregnant or potentially pregnant women and nursing mothers only when necessary. Safety in children has not been fully established, so caution is necessary. This medication is primarily excreted via the kidneys, so elderly patients may require dosage adjustments due to decreased kidney function. Overdose is rarely associated with specific symptoms, but treatment may include vomiting or gastric lavage as appropriate. This medication should be stored out of the reach of children and should not be transferred to other containers. Long-term use may affect the eyes, so it is advisable to undergo ophthalmic examinations.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container that blocks light and in a dry place free from moisture. This storage method will help maintain the efficacy of the medication for a longer period.
White round film-coated tablet
30 tablets/bottle, 500 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Ranitidine Hydrochloride 168mg
Tablet · Prescription medication
Iworld Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 168mg
Prescription medication
Ildong Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 168mg
Tablet · Prescription medication
Hana Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 56mg
Prescription medication
Ildong Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 336mg
Prescription medication
Ildong Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 168mg
Tablet · Prescription medication
Hanin Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 112mg
Solution · Prescription medication
Hanin Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 56mg
Solution · Prescription medication
Hanin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.